Table 1.
n = 112 (%) | |
---|---|
Treatment | |
Anti-malarial drugs | |
(Hydroxy)chloroquinea | 69 (62) |
Mefloquine | |
Vaccines | 1 (1) |
BCG vaccine | 12 (11) |
Mycobacterium w | 1 (1) |
Mycobacterium s manresensis | 1 (1) |
Measles vaccines | 1 (1) |
Antiviral drugs | |
Lopinavir/Ritonavir | 3 (3) |
Nitazoxanide | 3 (3) |
Interferonb | 2 (2) |
Nitric oxide | 2 (2) |
Tenofovir + emtricitabine | 2 (2) |
Bromhexine | 2 (2) |
Arbidol | 2 (2) |
Favipiravir | 1 (1) |
Antibiotics and antiseptics | |
Azithromycin | 3 (3) |
Ivermectin | 2 (2) |
Povidone-iodine | 2 (2) |
Probiotics | |
Immune modulators | |
Lactobacillus coryniformis K8 | 1 (1) |
Convalescent serum or purified immunoglobulins | 3 (3) |
PUL-042 inhalation | 1 (1) |
Quercetin | 1 (1) |
QuadraMune | 1 (1) |
Lactoferrin | 1 (1) |
Levamisole + isoprinosine | 1 (1) |
Others | |
Thiazide + calcium blocker | 1 (1) |
Mesenchymal stem cells | 1 (1) |
Melatonin | 1 (1) |
Targeted populationc | |
Medical workers | 70 (63) |
Patients relatives | 20 (18) |
At-risk individuals | 14 (13) |
Others | 16 (14) |
Administration moded | |
Oral | 83 (78) |
Intradermal | 14 (13) |
Inhaled/spray | 6 (6) |
Intravenous | 2 (2) |
Others | 2 (2) |
Unspecified | 6 (6) |
Study design | |
Randomized | 98 (88) |
Non-randomized | 13 (12) |
Unspecified | 1 (1) |
Total number of planned inclusions | |
200 and less | 26 (23) |
201–999 | 47 (42) |
1000 and more | 38 (34) |
Unspecified | 1 (1) |
9 trials included an association of hydroxychloroquine with other drugs: hydroxychloroquine + azithromycin (two trials), hydroxychloroquine + arbidol (two trials), hydroxychloroquine + bromhexine, hydroxychloroquine + tenofovir + emtricitabine, hydroxychloroquine + lopinavir/ritonavir (two trials), hydroxychloroquine + ivermectin + zinc + vitamin C + povidone-iodine.
Interferons are simultaneously immune modulators and antivirals.
8 trials included several categories.
1 trial included both inhaled and oral treatments.